The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents

British Journal of Pharmacology

Volumn 169, Issue 8, 2013, Pages 1824-1839

  Sławińska, Anna ^a   Wierońska, Joanna M ^a   Stachowicz, Katarzyna ^a   Marciniak, Marcin ^a   Łasoń Tyburkiewicz, Magdalena ^a   Gruca, Piotr ^a   Papp, Mariusz ^a   Kusek, Magdalena ^a   Tokarski, Krzysztof ^a   Doller, Darío ^b,c   Pilc, Andrzej ^a,d  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b H LUNDBECK A S   (Denmark)

^c LUNDBECK RESEARCH USA   (United States)

^d JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Lu AF21934; Lu AF32615; mGlu receptors; positive allosteric modulation; schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; LU AF 21934; LU AF 32615; METABOTROPIC RECEPTOR 4; N1 (3,4 DICHLOROPHENYL)CYCLOHEXANE 1,2 DICARBOXAMIDE; NEUROLEPTIC AGENT; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; EXCITATORY POSTSYNAPTIC POTENTIAL; HYPERACTIVITY; MALE; MENTAL TASK; MOUSE; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; RODENT; SCHIZOPHRENIA; SOCIAL INTERACTION;

LU AF21934; LU AF32615; MGLU RECEPTORS; POSITIVE ALLOSTERIC MODULATION; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; AMPHETAMINE; ANILIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; HYPERKINESIS; MALE; MICE; MOTOR ACTIVITY; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84881344699     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12254     Document Type: Article

References (64)

1. Acher FC, Tellier FJ, Azerad R, Brabet IN, Fagni L, Pin JP, (1997). Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem 40: 3119-3129.
2. Addex Therapeutics website. ADX 71149. Available at: http://www. addextherapeutics.com/rd/pipeline/adx71149-for-schizophrenia (accessed September 7, 2012).
3. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. Aultman JM, Moghaddam B, (2001). Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berl) 153: 353-364.
5. Benítez R, Fernández-Capetillo O, Lázaro E, Mateos JM, Osorio A, Elezgarai I, et al. (2000). Immunocytochemical localization of the metabotropic glutamate receptor mGluR4a in the piriform cortex of the rat. J Comp Neurol 417: 263-274.
6. Bennouar KE, Uberti MA, Melon C, Bacolod MD, Jimenez HN, Cajina M, et al. (2013). Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology 66: 158-169.
7. Beurrier C, Lopez S, Révy D, Selvam C, Goudet C, Lhérondel M, et al. (2009). Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 23: 3619-3628.
8. Conn PJ, Christopoulos A, Lindsley CW, (2009a). Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8: 41-54.
9. Conn PJ, Lindsley CW, Jones CK, (2009b). Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30: 25-31.
10. Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, et al. (1993). Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 45: 9-17.
11. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, et al. (1995). Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120: 67-74.
12. Corti C, Aldegheri L, Somogyi P, Ferraguti F, (2002). Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience 110: 403-420.
13. Coyle JT, Tsai G, (2004). The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174: 32-38.
14. Cramer P, Bowen J, O'Neill M, (1992). Schizophrenics and social judgement. Why do schizophrenics get it wrong? Br J Psychiatry 160: 481-487.
15. Dudchenko PA, (2004). An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev 28: 699-709.
16. Duty S, (2010). Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol 161: 271-287.
17. East SP, Bamford S, Dietz MG, Eickmeier C, Flegg A, Ferger B, et al. (2010). An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg Med Chem Lett 20: 4901-4905.
18. Geyer MA, Ellenbroek B, (2003). Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1071-1079.
19. Hammarlund-Udenaes M, (2010). Active-site concentrations of chemicals-are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106: 215-220.
20. Holmes A, Lit Q, Murphy DL, Gold E, Crawley JN, (2003). Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav 2: 365-380.
21. Jacobs BL, Trulson ME, (1979). Mechanisms of action of LSD. Am Sci 67: 396-404.
22. Javitt DC, (1987). Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9: 12-35.
23. Jones CA, Brown AM, Auer DP, Fone KC, (2011a). The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology (Berl) 214: 269-283.
24. Jones CA, Watson DJG, Fone KCF, (2011b). Animal models of schizophrenia. Br J Pharmacol 164: 1162-1194.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
26. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. (2011). A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31: 349-355.
27. Kłodzinska A, Bijak M, Tokarski K, Pilc A, (2002). Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 73: 327-332.
28. Leite JV, Guimarães FS, Moreira FA, (2008). Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 578: 222-227.
29. Lindsley CW, Hopkins CR, (2012). Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature. Expert Opin Ther Pat 22: 461-481.
30. Lira A, Zhou M, Castanon N, Ansorge MS, Gordon JA, Francis JH, et al. (2003). Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry 54: 960-971.
31. Lopez S, Jouve L, Turle-Lorenzo N, Kerkerian-Legoff L, Salin P, Amalric M, (2012). Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity. Neurobiol Dis 46: 69-77.
32. McCormick DA, Connors BW, Lighthall JW, Prince DA, (1985). Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. J Neurophysiol 54: 782-806.
33. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK, (2000). Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292: 76-87.
35. Marino MJ, Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK, et al. (2006). Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A 100: 13668-13673.
36. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, et al. (2012). Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 55: 1445-1464.
37. Moghaddam B, Jackson ME, (2003). Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci 1003: 131-137.
38. Mueser KT, McGurk SR, (2004). Schizophrenia. Lancet 363: 2063-2072.
39. Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D, et al. (1998). Glutamate receptors: brain function and signal transduction. Brain Res Brain Res Rev 26: 230-235.
40. Pałucha-Poniewiera A, Kłodzińska A, Stachowicz K, Tokarski K, Hess G, Schann S, et al. (2008). Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 55: 517-524.
41. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13: 1102-1107.
42. Pin JP, Duvoisin R, (1995). The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34: 1-26.
43. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, et al. (2007a). In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193: 121-136.
44. Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, et al. (2007b). Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2- sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 321: 308-317.
45. Sams-Dodd F, (1995). Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol 6: 55-65.
46. Sams-Dodd F, (1996). Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7: 3-23.
47. Sams-Dodd F, (1997). Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8: 196-215.
48. Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, et al. (2009). Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5- methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther 330: 179-190.
49. Schoepp DD, Marek GJ, (2002). Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1: 215-225.
50. Sheffler DJ, Gregory KJ, Rook JM, Conn PJ, (2011). Allosteric modulation of metabotropic glutamate receptors. Adv Pharmacol 62: 37-77.
51. Sibille P, Lopez S, Brabet I, Valenti O, Oueslati N, Gaven F, et al. (2007). Synthesis and biological evaluation of 1-amino-2- phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J Med Chem 50: 3585-3595.
52. Sławińska A, Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Uberti MA, Bacolod MA, et al. (2013). Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu(4) receptor. Neuropharmacology 66: 225-235.
53. Valenti O, Marino MJ, Wittmann M, Lis E, DiLella AG, Kinney GG, et al. (2003). Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci 23: 7218-7226.
54. Van der Kloot W, (1991). The regulation of quantal size. Prog Neurobiol 36: 93-130.
55. Verma A, Moghaddam B, (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373-379.
56. Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, et al. (2001). Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav 69: 643-652.
57. Wang X, Ai J, Hampson DR, Snead OC 3rd, (2005). Altered glutamate and GABA release within thalamocortical circuitry in metabotropic glutamate receptor 4 knockout mice. Neuroscience 134: 1195-1203.
58. Wedzony K, Mac̈kowiak M, Zajaczkowski W, Fijał K, Chocyk A, Czyrak A, (2000). WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23: 547-559.
59. Weinberger DR, (2007). Schizophrenia drug says goodbye to dopamine. Nat Med 13: 1018-1019.
60. Wierońska JM, Kłak K, Pałucha A, Brański P, Pilc A, (2007). Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res 1184: 88-95.
61. Wierońska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A, (2011). The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. Br J Pharmacol 163: 1034-1047.
62. Wierońska JM, Stachowicz K, Acher F, Lech T, Pilc A, (2012). Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl) 220: 481-494.
63. Wierońska JM, Acher FC, Sławińska A, Gruca P, Łasoń-Tyburkiewicz M, Papp M, et al. (2013). The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signaling. Psychopharmacology (Berl) 227: 711-725.
64. Wischhof L, Aho HE, Koch M, (2012). DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation. Pharmacol Biochem Behav 102: 6-12.